01 Automation and High-Throughput Systems Improve Capillary Electrophoresis Workflows The capillary electrophoresis market is increasingly moving toward automated, multi-capillary, and high-throughput systems that reduce manual intervention and improve testing efficiency. Automation is particularly valuable in pharmaceutical and biotechnology laboratories, where protein characterization, purity assessment, and quality control require repeatable and quantitative analysis. The integration of advanced detection technologies is also improving sensitivity and enabling laboratories to process more samples within shorter workflows. In September 2025, SCIEX launched native fluorescence detection for its BioPhase 8800 system, enhancing CE-SDS and cIEF workflows used to assess critical quality attributes of protein therapeutics. The technology improves detection of low-abundance peaks and supports more sensitive characterization of purity, fragmentation, aggregation, and post-translational modifications.
02 Integration With Genomic and Clinical Testing Expands CE Applications Capillary electrophoresis is increasingly being integrated into genomic analysis, Sanger sequencing, fragment analysis, clinical diagnostics, and precision medicine workflows.This expansion is supported by the growing need for reliable, rapid, and high-resolution molecular analysis in clinical and research environments. In April 2025, Thermo Fisher Scientific introduced the Applied Biosystems SeqStudio Flex Dx Genetic Analyzer, an IVDR-compliant capillary electrophoresis system designed for clinical and research applications involving Sanger sequencing and fragment analysis in targeted genomic testing. The launch demonstrates the continued integration of CE technology into regulated clinical and genomic workflows.
01 Expansion of Precision Medicine and Genomic Testing Strengthens CE Demand The growing use of personalized medicine, genomic testing, and molecular diagnostics is supporting demand for capillary electrophoresis. CE enables high-resolution analysis of nucleic acids, proteins, and other biomolecules and remains important for applications such as Sanger sequencing, fragment analysis, genetic testing, and biopharmaceutical characterization. As healthcare systems increasingly adopt targeted therapies and biomarker-driven treatment, laboratories require accurate analytical technologies capable of supporting complex molecular workflows.
01 High Infrastructure and Equipment Costs Limit Access to Advanced CE Systems Capillary electrophoresis systems can require significant investment in sophisticated instruments, laboratory infrastructure, consumables, maintenance, and trained personnel. Advanced platforms used for genomic and biopharmaceutical analysis may also require specialized technical expertise, creating challenges for smaller laboratories and academic institutions with limited budgets. These financial and operational requirements can slow adoption in emerging markets and restrict access to high-complexity testing capabilities.
01 National Genomics Programs Create New Demand for CE-Based Genetic Analysis Government-backed genomics programs and private-sector investments in population sequencing are creating opportunities for capillary electrophoresis technologies. Large-scale genomic initiatives require reliable analytical platforms for sequencing, fragment analysis, variant identification, and validation of genetic findings. As countries expand genomic databases and integrate genetic information into clinical research and precision medicine, CE systems can benefit from increased demand for targeted sequencing and confirmatory analysis.
01 Increasing Competition From Next-Generation Sequencing Platforms Pressures CE Adoption The rapid advancement of next-generation sequencing (NGS) technologies presents a significant challenge for the capillary electrophoresis market. NGS can process large volumes of genetic information simultaneously and is increasingly used for whole-genome, whole-exome, and targeted sequencing. CE manufacturers therefore need to demonstrate advantages in areas such as accuracy, speed, workflow simplicity, cost efficiency, and targeted analysis while integrating their systems with broader genomic workflows.
May 2026 SCIEX expanded its capillary electrophoresis portfolio with next-generation analytical systems designed to improve sensitivity, automation, and throughput for biopharmaceutical characterization and life science research.
February 2026 Agilent Technologies introduced advanced capillary electrophoresis solutions featuring enhanced data analysis capabilities and improved reproducibility for pharmaceutical and clinical laboratories.
October 2025 Thermo Fisher Scientific launched upgraded capillary electrophoresis instruments with integrated automation and high-resolution separation technologies to accelerate genomic and proteomic workflows.
June 2025 Bio-Rad Laboratories expanded its electrophoresis product portfolio with enhanced capillary-based platforms for nucleic acid and protein analysis in research and diagnostic applications.